GlaxoSmithKline is providing pandemic adjuvant technology to another company to bolster the chances of developing a vaccine against COVID-19.
Britain’s GSK said an injection of the company’s cabotegravir drug given every two months was found to be 65 percent more effective in preventing HIV infections than Gilead’s Truvada daily oral pills.
As companies scramble to develop a vaccine against the SARS-CoV-2 virus, a team of husband and wife researchers have found that the measles, mumps, rubella (MMR) vaccine can reduce the symptoms of COVID-19.
Menlo Park, California-based Orca Bio closed on a Series D financing worth $192 million, bringing the total raised since 2016 to $300 million.
AstraZeneca’s cancer drug Calquence has shown initial signs of helping hospitalized COVID-19 patients get through the worst of the disease, as researchers scramble to repurpose existing treatments to help fight the deadly infection.
Prellis Biologics Inc. generated 300 human IgG antibodies that bind to either the S1 or S2 spike protein of the SARS-CoV2-Wuhan strain of the novel coronavirus.
The U.S. Food and Drug Administration approved Tecentriq as a standalone therapy for an advanced form of lung cancer.
The U.S. Food and Drug Administration approved Bristol Myers Squibb Co.’s combination therapy for previously untreated patients with a form of lung cancer, a much-needed boost as the company battles the dominance of Merck’s Keytruda.
As the mortality figures for COVID-19 continued to rise, people are wondering where they will stop. The actual death toll for COVID-19 will not be calculable for some time, but there are early indications that the mortality rate may be significantly lower than calculations of deaths per confirmed cases lead one to believe.
Geneius Biotechnology is developing T cells as a quasi-personalized, off-the-shelf, therapy and preventive measure against COVID-19.